The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine.

Creator(s)

Elizabeth Fraley, Children's Mercy HospitalFollow
Cas LeMaster, Children's Mercy HospitalFollow
Santosh Khanal, Children's Mercy HospitalFollow
Dithi Banerjee, Children's Mercy HospitalFollow
T Pastinen, Children's Mercy HospitalFollow
Elin Grundberg, Children's Mercy HospitalFollow
Rangaraj Selvarangan, Children's Mercy HospitalFollow
Todd Bradley, Children's Mercy HospitalFollow

Document Type

Article

Publication Date

8-24-2022

Identifier

DOI: 10.1093/cid/ciab850; PMCID: PMC8522412

Abstract

Determining the duration of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical for informing the timing of booster immunization. Many genetic and environmental factors could influence both the magnitude and persistence of the antibody response. Here, we showed that SARS-CoV-2 infection before vaccination and age affected the decay of antibody responses to the SARS-CoV-2 messenger RNA vaccine.

Journal Title

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

Volume

75

Issue

1

First Page

902

Last Page

904

MeSH Keywords

Antibodies, Viral; COVID-19; COVID-19 Vaccines; Humans; SARS-CoV-2; Vaccination; Vaccines, Synthetic; Viral Vaccines; mRNA Vaccines

Keywords

19; 2; Antibody response; COVID; CoV; SARS; Vaccine

Comments

Grant support

• 00001670/Children's Mercy Institutional Review Board

Recommended Citation

Fraley E, LeMaster C, Khanal S, et al. The Impact of Prior Infection and Age on Antibody Persistence After Severe Acute Respiratory Syndrome Coronavirus 2 Messenger RNA Vaccine. Clin Infect Dis. 2022;75(1):e902-e904. doi:10.1093/cid/ciab850